Highest-materiality recent filing
Zai Lab shareholders approve all 14 proposals at 2026 AGM; advisory pay vote sees 28% dissent
All director nominees re-elected; Diekman and Wirth had highest against votes (~39M and ~38M).
Zai Lab President & COO Josh Smiley departs; responsibilities absorbed by CEO
Josh Smiley ceases as President and COO effective May 18, 2026; last day is May 22, 2026.
Zai Lab Q1 2026 revenue $99.6M (-6% YoY); net loss $51M; zoci shows 62.5% intracranial ORR
Total revenues $99.6M, down 6% YoY; product revenue $95.6M (-10% YoY); ZEJULA fell to $30M from $49.5M.
Zai Lab Q4 total revenue $127.6M (+17% YoY); net loss narrows to $50.4M
Q4 product revenue $127.1M (+17% YoY); ZEJULA $56M (+16%), XACDURO $10.7M (+225%).
Zai Lab Q3 revenue up 14% to $116.1M; loss narrows; revises FY2025 guidance to at least $460M
Product revenue $115.4M (+13% YoY); VYVGART $27.7M, ZEJULA $42.4M, NUZYRA $15.4M.
Zai Lab secures RMB300M ($42.1M) revolving credit facility from Industrial Bank for working capital
Guarantee and credit line contract with Industrial Bank for up to RMB300M (~$42.1M) to Zai Lab Shanghai.
Zai Lab Q2 revenue grows 9% YoY to $110M; operating loss improves 28%; targets Q4 profitability
Product revenue $109.1M (+9% YoY); VYVGART sales $26.5M (+46% QoQ); ZEJULA $41.0M (down from $45M YoY).
Zai Lab shareholders approve all 14 proposals at 2025 AGM
All director nominees re-elected, including Samantha Du, John Diekman, Richard Gaynor, Nisa Leung, William Lis, Scott Morrison, Leon Moulder, Michel Vounatsos, and Peter Wirth.
Zai Lab Q1 revenue up 22% to $106.5M; operating loss narrows 20%; on track for Q4 profitability
Product revenue $105.7M (+21% YoY); VYVGART $18.1M, ZEJULA $49.5M, NUZYRA $15.1M.
Zai Lab Q4 2024 revenue $109.1M (+66% YoY); guides FY2025 revenue $560-590M
Total revenues $399.0M for FY2024, up 50% YoY; product revenue $397.6M, up 49% YoY.
Zai Lab secures RMB300M ($41.1M) revolving credit facility from Bank of Communications
Guarantee and loan contract signed Jan 2, 2025 with BOCOM for working capital loans to subsidiary Zai Lab Shanghai.
Priced underwritten public offering of 7,843,137 ADSs at $25.50 per ADS; expected gross proceeds ~$200M.
Zai Lab updates risks: employee medical fraud probes in China, Optune patent setbacks
Several current/former employees in ZEJULA sales team under criminal investigation by Chinese authorities for alleged medical insurance fraud; individuals detained or under compulsory measures.
Zai Lab Q3 net product revenue rises 47% YoY to $101.8M; KarXT bridging study positive
Net product revenue $101.8M, up 47% YoY; net loss $41.7M ($0.42/ADS loss).
Zai Lab Q2 net product revenue $100.1M (+45% YoY); narrows net loss to $80.3M
Net product revenue $100.1M, up 45% YoY (47% at CER); VYVGART contributed $23.2M vs $0.1M YoY.
Zai Lab secures RMB250M credit facility from China Merchants Bank for subsidiary working capital
Parent company issued guarantee to China Merchants Bank (Shanghai) for loans up to RMB250M (~$34.4M) for wholly owned subsidiary Zai Lab Shanghai.
Zai Lab shareholders approve 2024 equity plan, re-elect all directors at AGM
2024 Equity Incentive Plan approved (568.4M for, 215.2M against), replacing 2022 Plan with more shares.
Zai Lab CMO Dr. Harald Reinhart to retire; Dr. Rafael Amado to lead all Global R&D
Dr. Harald Reinhart, President, Head of Global Development (NSAiID), retiring effective June 30, 2024.
Zai Lab Q1 product revenue $87.1M (+39% YoY); net loss $53.5M, VYVGART sales $13.2M
Product revenue $87.1M (+39% YoY; +43% at CER); ZEJULA $45.5M (+7%), VYVGART $13.2M (launch Sep 2023).
Zai Lab FY2023 product revenue $266.7M (+25% YoY); VYVGART launch drives 2024 outlook >$70M
Product revenue $266.7M (+25% YoY; +31% CER); net loss narrowed to $334.6M from $443.3M.
Zai Lab enters debt facilities with three Chinese banks for up to ~$174M
BOC HK facility: $100M uncommitted, one-year term; $50M standby L/C issued; Zai Lab Shanghai draws RMB340M (~$47.8M) loan at ~2.95%.
Zai Lab Q3 revenue $69.2M (+22% YoY); launches VYVGART in China, net loss narrows
Product revenue $69.2M, up 22% YoY; VYVGART contributed $4.9M since September launch.
Zai Lab Q2 product rev $68.9M (+45% YoY); VYVGART approved in China; net loss $120.9M
Product revenue $68.9M, up 45% YoY (53% constant currency); driven by ZEJULA $43.0M, Optune $13.7M.
Zai Lab promotes Yajing Chen to CFO, replacing Billy Cho effective July 7
Yajing Chen promoted to CFO effective July 7, 2023; she was previously Deputy CFO.
China NMPA approves Zai Lab's VYVGART for generalized myasthenia gravis
NMPA approved VYVGART (efgartigimod alfa) as add-on for anti-AChR+ gMG adults.
Zai Lab 2023 AGM: directors re-elected, share mandate approved, exec compensation passes
All director nominees re-elected except Michel Vounatsos (elected as new director); each with >85% support.
TTFields + standard therapies improved median OS from 9.9 to 13.2 months (HR 0.74, p=0.035) in post-platinum metastatic NSCLC.
Zai Lab Q1 product revenue $62.8M, up 36% YoY; net loss narrows to $49.1M
Product revenue $62.8M (+36% YoY); ZEJULA $42.7M (+44% YoY); Optune $13.3M; QINLOCK $1.3M; NUZYRA $5.5M.
Zai Lab reports temporary HKEX trading suspension resolved same day after publishing annual results
Trading in Zai Lab shares on HKEX suspended at 9:06 a.m. on March 31, 2023 pending publication of annual results.
Zai Lab Reports Full-Year 2022 Revenue of $215M, Up 49% YoY
Total revenue $215.0M in 2022, a 49.0% increase year-over-year; ZEJULA revenue $145.2M, up 55.2%.
Zai Lab appoints former Biogen CEO Michel Vounatsos as independent director
Appointed Michel Vounatsos independent director effective Jan 7, 2023; chairs Commercial Committee and serves on R&D.
Zai Lab partner Novocure's LUNAR study meets primary overall survival endpoint in stage 4 NSCLC
LUNAR study showed statistically significant and clinically meaningful improvement in overall survival vs standard therapies alone.
Zai Lab Q3 revenue $57.5M (+33% YoY); net loss widens to $161.2M on Seagen payment
Total revenues $57.5M vs $43.1M YoY; net product revenue led by ZEJULA $39.2M.
Zai Lab officer Alan Sandler resigns effective Oct 28, 2022; severance agreement signed
Dr. Alan Sandler resigns effective October 28, 2022 to pursue another professional opportunity.
Zai Lab pays $30M upfront, up to $78M in dev/reg milestones, and up to $185M in sales milestones.
Zai Lab Q2 2022 revenue $48.2M (+31% YoY); net loss narrows; efgartigimod BLA accepted in China
Total revenues $48.2M (Q2 2021: $36.9M); ZEJULA revenue $34.1M (+46% YoY). Net loss $137.9M vs $163.3M.
Zai Lab appoints Joshua Smiley as COO, effective August 1, 2022
Joshua Smiley appointed COO; previously Eli Lilly SVP and CFO since 1995.
Zai Lab shareholders approve 2022 Equity Plan and amended Articles for HK dual-primary listing
Shareholders approved 2022 Equity Incentive Plan (97,908,743 shares) conditioned on HKEX dual-primary listing becoming effective.
Zai Lab appoints KPMG as new auditor; dismisses Deloitte effective May 31, 2022
KPMG LLP engaged as independent registered public accounting firm for FY2022, effective May 31, 2022.
Zai Lab receives HKSE acknowledgement for dual-primary listing effective June 27, 2022
HKSE acknowledged Zai Lab's application for voluntary conversion from secondary to dual-primary listing.
Zai Lab Q1 2022 results; excerpts lack financials; auditor, share split, COO announced
Announced Q1 2022 financial results on May 10, 2022; specific revenue and earnings figures not visible in the provided excerpt.
Zai Lab dismisses Deloitte, appoints KPMG as auditor for FY2022
Audit Committee approved engagement of KPMG LLP for FY2022 SEC and HK Stock Exchange filings, subject to regulatory approvals.
Zai Lab engages KPMG as US auditor to comply with HFCAA and maintain Nasdaq listing
Engaged KPMG LLP as independent auditor for FY2022, replacing Deloitte.
Zai Lab CSO Tao Fu resigns effective April 8, 2022
Tao Fu, Chief Strategy Officer, notified Zai Lab of resignation on March 28, 2022.
Zai Lab shareholders approve 10-for-1 share subdivision effective March 30, 2022
Subdivision approved by 82,350,538 votes for vs 21,786 against and 5,788 abstentions.
Zai Lab appoints Joshua Smiley as COO effective August 1, 2022
Joshua Smiley appointed Chief Operating Officer, effective August 1, 2022, reporting to CEO Samantha Du.
Zai Lab reports FY2021 results; financial details not provided in 8-K exhibit
Announced financial results for FY2021; specific revenue and EPS figures not provided in the filing.
Zai Lab's NDA for margetuximab accepted by China NMPA for HER2+ breast cancer
NMPA accepted NDA for margetuximab, a HER2-targeted monoclonal antibody, for metastatic HER2+ breast cancer with 2+ prior anti-HER2 therapies.
Zai Lab promotes Harald Reinhart to President and Head of Global Development
Harald Reinhart, M.D., promoted from CMO to President and Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases
NMPA approves Zai Lab's NUZYRA as Category 1 innovative drug for CABP and ABSSSI
NMPA approved NUZYRA (omadacycline) for community-acquired bacterial pneumonia and acute bacterial skin infections.
On May 18, 2026, the Board of Directors of Zai Lab Limited (the “Company”) determined that Mr. Josh Smiley will cease serving as President and Chief Operating Officer of the Company, effective as of May 18, 2026, and his last day of employment with the Company will be May 22, 2026.
On June 11, 2024 , Zai Lab Limited (the “Company”) announced that Dr. Harald Reinhart, President, Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases, has informed the Company that he has decided to retire, effective June 30, 2024.
Also on July 6, the Company announced that Dr. Chen will be succeeding William Cho, who is stepping down from his role as Chief Financial Officer, effective July 7, 2023.
On July 6, 2023, Zai Lab Limited (the “Company”) announced that it has appointed Dr. Yajing Chen as its Chief Financial Officer, effective July 7, 2023.
On January 7, 2023, the Board of Directors (the “Board”) of Zai Lab Limited (the “Company”) appointed Michel Vounatsos as an independent director, effective immediately.
Dr. Alan Sandler who provided notice that he is resigning from the Company, effective October 28, 2022, to pursue another professional opportunity.
Zai Lab Limited (the “Company”) appointed Joshua Smiley as the Company’s Chief Operating Officer, effective on August 1, 2022
On March 28, 2022, Tao Fu, Chief Strategy Officer of Zai Lab Limited (the “Company”), provided notice to the Company of his resignation from the Company, effective as of the close of business on April 8, 2022.
On March 15, 2022, Zai Lab Limited (the “Company”) announced the appointment of Joshua Smiley as the Company’s Chief Operating Officer.
On December 22, 2021, Zai Lab Limited (the “Company”) announced the promotion of Harald Reinhart, M.D., from his current role as Chief Medical Officer to President and Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases.
On November 19, 2021 (U.S. Eastern Time), the Board of Directors (the “Board”) of Zai Lab Limited (the “Company”) appointed Richard Gaynor as an independent director, effective immediately.
On October 13, 2021 (U.S. Eastern Time), the Board of Directors (the “Board”) of Zai Lab Limited (the “Company”) appointed Scott W. Morrison as an independent director, effective immediately.
Max materiality 0.85 · Median 0.65 · Most common event earnings